Engflag

Ansielix

Quick links to important sections

Ansielix

Ansielix_EN

Method of action: Antianxiety, Anticonvulsant, Antidepressant, Anxiolytic, Hypnotic, Muscle Relaxant, Psycholeptics, Tranquilizing

Treatment option: Agoraphobia, Pain, Chest Pain, Generalized Anxiety Disorder, Depression, Neurosis, Panic, Anxiety&Panic Attacks, Panic Attacks And Panic Disorder, Paresthesia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ansielix

Quick Facts

Property Description
Active ingredient Alprazolam
Form Oral tablet (Immediate and Extended Release)
Pharmacological class Benzodiazepine / Anxiolytic
General purpose Short-term relief of severe anxiety symptoms
Origin Synthetic compound

Ansielix is a synthetic, single-ingredient medication identified by the active compound Alprazolam, which functions as a potent Central Nervous System (CNS) depressant. This medication belongs to the Benzodiazepine class of drugs, specifically categorized as a triazolo-benzodiazepine, a structure recognized for its high efficacy in promoting a calming state.

What Type of Medication is Ansielix?

Ansielix is chemically classified as a Benzodiazepine and acts primarily as an anxiolytic, meaning its main function is to alleviate feelings of anxiety and tension. Drugs containing Alprazolam are part of the benzodiazepine class, which are prescribed for managing anxiety. This pharmacological action is widely clinically recognized for its utility in mitigating episodes of intense worry.

While sharing core functional mechanisms with other benzodiazepines, Alprazolam is recognized for its high potency. This differentiating feature involves a swift and pronounced impact compared to many longer-acting compounds within the same broad class.

Alprazolam: Composition and Pharmaceutical Form

The core composition of Ansielix is its active ingredient, Alprazolam, which is a pure synthetic compound. As an oral formulation, the medication is provided as a tablet for ingestion via the oral route. To meet different needs, Ansielix can be produced in various forms, including an immediate-release tablet for rapid onset and an extended-release tablet which utilizes specialized solid excipients to distribute the active ingredient gradually over a sustained timeframe. This dual availability offers distinct patient-oriented options for managing different temporal requirements of anxiety relief.

General Purpose: How Ansielix Supports the Central Nervous System

The general purpose of Ansielix is to provide short-term relief from acute symptoms of anxiety, apprehension, and tension by interacting with the central nervous system. It achieves this by boosting the effect of the brain's natural calming agent, gamma-Aminobutyric acid (GABA), which is the primary inhibitory neurotransmitter. This mechanism helps slow down overactive nerve signals, which results in a calming and stabilizing effect.

What side effects are possible with Ansielix?

The safety profile of Ansielix (Alprazolam) is structured around effects related to its action as a Central Nervous System (CNS) depressant and serious risks highlighted in official regulatory labeling.

Frequency-Classified Adverse Reactions

The most frequent adverse reactions are classified based on regulatory standards:

  • Very Common (occurring in ge 1 out of 10 people): Sedation and Somnolence (drowsiness).
  • Common (occurring in ge 1 out of 100 people): Effects on the Nervous System (Dizziness, Ataxia/impaired coordination, Memory impairment, Fatigue) and the Gastrointestinal System (Dry Mouth, Constipation). Common effects also include changes in appetite/weight and depression.

Reactions whose frequency is Not Known (reported in post-marketing data) include serious conditions such as hepatic failure and angioedema (swelling of the face or throat).

Serious Safety Risks and Dependence

Official labeling includes specific statements regarding significant safety risks associated with this medication:

  • Abuse, Misuse, and Addiction: Use may expose individuals to risks of abuse, misuse, and addiction, which can lead to overdose or death, and these risks increase with higher doses and longer treatment duration.
  • Physical Dependence and Withdrawal: The development of clinically significant physical dependence is documented. Abrupt discontinuation can lead to severe withdrawal reactions, including life-threatening seizures, with the greatest risk noted 24–72 hours after stopping the medication.
  • Opioid Interaction: Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death.

Population-Specific Safety Considerations

Safety statements address specific patient groups:

  • Older Adults (Geriatric): This group is more likely to experience increased unwanted CNS effects, such as unsteadiness or dizziness, increasing the documented risk of falls.
  • Severe Hepatic Impairment: The medication is contraindicated in patients with severe liver dysfunction.
  • Pregnancy: Use during later stages of pregnancy can result in neonatal withdrawal syndrome or neonatal sedation in the newborn.

Use is also contraindicated in patients with known hypersensitivity to benzodiazepines and in those with acute narrow-angle glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Ansielix (Alprazolam) overdose as an exaggeration of its core CNS depressant effects. Documented overdose manifestations include a spectrum of CNS signs, such as somnolence, confusion, impaired coordination (ataxia), slurred speech, and a reduction in reflexes. This condition requires immediate attention due to the documented risk of progression to severe, life-threatening outcomes.

Regulatory-Mandated Emergency Actions

The most severe manifestations of overdose include coma, respiratory depression (slowed or shallow breathing), and potentially death. Regulatory authorities state that immediate medical attention must be sought for any suspected overdose.

Urgent medical help is required when specific severe signs are observed, such as having slow breathing with long pauses, if the lips appear discolored, or if the individual cannot be awakened. Emergency services must be contacted immediately under these conditions.

Management and Special Considerations

In a supervised setting, management centers on symptomatic and supportive treatment, which includes maintaining the airway and monitoring vital signs. The regulatory profile notes that a specific antagonist, Flumazenil, is available for complete or partial reversal of sedative effects, though its use is restricted due to potential adverse effects.

Special consideration is noted for geriatric patients and individuals with impaired hepatic or renal function, as regulatory documents indicate they may face an increased risk of toxicity due to changes in drug clearance.

Therapeutic Uses of Ansielix

What Ansielix Treats: Main Uses and Benefits

The active ingredient in Ansielix is commonly used to help with the symptomatic management in acute phases of generalized anxiety disorder and the symptomatic management of panic disorder in adults. Ansielix is relevant for easing symptoms that are grouped into two primary conditions: Generalized Anxiety Disorder (GAD) and Panic Disorder, including acute episodes of intense fear.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, where individuals experience excessive, chronic worry and pronounced physical manifestations. It provides support that helps ease the overall symptom burden of these conditions, and may help with the cluster of symptoms associated with these diagnoses.

Quick Fact: Relief for Acute Anxiety and Panic

Ansielix may assist with managing the high levels of emotional distress, cognitive worry, and somatic symptoms, such as muscle tension and trembling, that characterize these acute conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ansielix?

Ansielix (Alprazolam) eligibility is strictly defined by regulatory documents, distinguishing between populations permitted, restricted, or contraindicated for use.

Contraindicated Populations (Must Not Use)

Category Restriction
Allergy Known hypersensitivity to alprazolam or any other benzodiazepine.
Comorbidities Acute Narrow-Angle Glaucoma, Severe Hepatic Insufficiency, Myasthenia Gravis, Severe Respiratory Insufficiency, and Sleep Apnoea Syndrome.
Interactions Concomitant use with strong CYP3A inhibitors, such as ketoconazole or itraconazole.

Restricted and Special Populations

Category Regulatory Status
Age (Pediatric) Not Recommended. Safety and efficacy are not established in individuals under 18 years of age.
Age (Elderly) Use requires caution. The lowest effective dose must be used due to increased risk of adverse effects.
Reproductive Status Not Recommended during pregnancy (FDA Category D) or while breastfeeding, due to documented risks to the fetus and infant.
Organ Function Caution is recommended for patients with impaired renal function or mild to moderate hepatic insufficiency.
Comorbidity Use requires the greatest caution in patients with a history of alcohol or drug dependence, or those with suicidal tendencies.

What should I know about interactions with other medicines?

Ansielix is subject to documented interactions that principally affect its clearance via metabolism and those that increase the risk of Central Nervous System (CNS) depression. This profile is structured by official warnings and restrictions stated in government labeling.

Interaction-Related Restrictions

Classification Interacting Agents (Examples) Official Regulatory Outcome
Contraindicated Combinations Ketoconazole, Itraconazole, and other strong CYP3A inhibitors These agents are formally prohibited for co-administration due to the significant impairment of Ansielix's metabolism, resulting in a documented increase in plasma concentrations and exposure (AUC) [Source 1.1, 1.2, 1.6].
Boxed Warning Combination Opioid medicines (e.g., Morphine, Oxycodone) The co-administration produces additive CNS depressant effects, which carries a Boxed Warning for the serious risks of profound sedation, respiratory depression, coma, and death [Source 1.6, 2.6].

Documented Interaction Mechanisms

Ansielix is primarily cleared through metabolism via the Cytochrome P450 3A (CYP3A) enzyme pathway. Interacting agents include both inhibitors and inducers of this enzyme [Source 1.1].

  • Exposure Modification (Increase): Potent CYP3A inhibitors, such as Nefazodone, Fluvoxamine, and Erythromycin, formally decrease the clearance of Ansielix [Source 1.1].
  • Exposure Modification (Decrease): CYP3A inducers, such as Carbamazepine and Cigarette Smoking, increase metabolism, leading to decreased Ansielix plasma levels [Source 1.1, 1.2].
  • Pharmacodynamic Reinforcement: Co-administration with Alcohol (Ethanol) and other CNS depressants (e.g., anticonvulsants, antihistamines) results in documented additive CNS depressant effects [Source 1.6, 2.2].

Other Documented Interactions

Ansielix may increase the plasma concentrations of certain tricyclic antidepressants, specifically Imipramine and Desipramine [Source 2.4]. A pharmacokinetic interaction has also been reported with Grapefruit Juice and the herbal product St. John's Wort [Source 3.3].

Mechanism of Action

How Ansielix Works

The action of Ansielix is centered on a targeted mechanism used to modulate activity within specific receptor or enzyme systems. It achieves this by focusing on key inhibitory signaling systems, contributing to the adjustment of systemic signaling patterns.

Targeted Receptor Modulation

Ansielix acts as a positive allosteric modulator (PAM) on specific central and peripheral receptor sites. It does not directly activate the receptor but increases the affinity or efficacy of the receptor for its natural mediator when it binds. This focused interaction is used to increase the functional activity of the targeted inhibitory system, initiating the core mechanistic cascade.

Adjusting Signaling Cascades

The enhancement of receptor activity initiates downstream signal transduction cascades that influence cellular membrane potential and ion flux. Ansielix's mechanism is relevant in systems characterized by rapid, heightened pathway activation, where it results in reduced downstream signaling magnitude and duration. This affects the propagation of activity of a given signal within widespread physiological processes.

Influencing System Dynamics

By intervening at the primary receptor and subsequent signaling steps, Ansielix influences the activity of central physiological systems that govern overall functional response. The resulting physiological effect is an adjustment of signaling activity, contributing to altered signaling dynamics within defined central pathways that shapes the drug's overall effect profile.

Dosage and Administration Information

Ansielix is administered via the oral route and is manufactured as both an immediate-release (IR) tablet and an extended-release (XR) tablet. Usage protocol is defined by specific guidelines for dosing, frequency, and administration constraints.

For Generalized Anxiety Disorder (GAD), the starting dose for the IR form is typically 0.25 mg to 0.5 mg total daily dose, which is divided and administered three times daily. The maximum total daily dose for this indication is 4 mg. For the management of Panic Disorder (PD), the starting dose is higher, typically 0.5 mg to 1 mg daily. The IR form is also taken three times daily, while the XR form is administered once daily, preferably in the morning, up to a maximum of 10 mg total daily dose for either form.

Administration and Procedural Rules

The administration procedure requires attention to the specific formulation. Immediate-release tablets can be taken without regard to food. In contrast, extended-release tablets must be swallowed whole and should not be crushed, divided, or chewed, as this alters the intended release pattern. Dosage is adjusted gradually, with increases occurring at intervals of every three to four days.

A key procedural rule governs discontinuation: when therapy is stopped, the dosage must be gradually reduced by no more than 0.5 mg every three days to conclude the course of treatment. Furthermore, specific administration rules apply to certain populations. Individuals who are geriatric or have severe hepatic impairment are indicated to begin with a reduced initial dose of 0.25 mg (IR) two or three times daily, or 0.5 mg (XR) once daily.

Recent Clinical Evidence

Ansielix: Recent Clinical Evidence

The active ingredient in Ansielix has been the focus of clinical study examining symptom intensity or variability in severe anxiety and panic. The research primarily consists of controlled clinical trials and regulatory reviews, which contribute to the evidence landscape regarding what has been observed in specific research settings.

Evidence Structure for Generalized Anxiety Disorder (GAD)

Research exploring GAD involved short-term, randomized, controlled trials (RCTs). These studies measured outcomes related to physical discomfort and anxiety severity using standardized rating scales (e.g., HAM-A). Findings describe patterns observed over limited treatment periods (up to four months). The existing research is limited by this short follow-up duration, meaning maintenance of effect is not fully established through systematic trials.

Evidence Structure for Panic Disorder (with or without Agoraphobia)

Ansielix was evaluated in settings involving acute episodes of panic using large-scale, short-term, placebo-controlled trials and regulatory meta-analyses. Studies monitored outcomes related to episodic changes, including panic attack count and frequency. Trial reports described measurements of change over the study duration (4–10 weeks). Some follow-up descriptions included patterns observed for up to eight months.

Evidence Gaps and Areas of Uncertainty

The regulated use of Ansielix is informed by studies with short treatment periods (4 to 10 weeks or up to 4 months). Because these durations were limited, long-term effects are not well characterized. Comparative evidence is lacking to show that Ansielix was associated with any unique pattern of outcomes compared to other medications in the same class.

Regulatory analyses note that the clinical data may reflect publication bias, meaning observed patterns may be overstated compared to the full set of trials. The available evidence is primarily derived from adult patients; data for pediatric patients remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Ansielix (FAQ)

Q: Can I take Ansielix if I have kidney problems?

Ansielix is primarily processed and removed by the kidneys. Therefore, it is important to discuss your kidney function with your healthcare provider before starting or continuing Ansielix. Taking Ansielix with significantly reduced kidney function may increase the risk of a very serious, but rare, side effect called lactic acidosis. Your healthcare provider will assess your kidney function using a blood test that measures your estimated glomerular filtration rate (eGFR). Ansielix is generally contraindicated (should not be used) in people with an eGFR below a specific level (typically below 30 mL/min/1.73 m^2).

Q: What is the most common side effect of Ansielix?

The most common side effects of Ansielix are related to the digestive system and include diarrhea, nausea, stomach upset, and gas. These symptoms are often most prominent when treatment begins or when the dosage is changed. The prescribing information for Ansielix typically suggests starting at a lower dose and gradually increasing it to minimize these effects. Furthermore, Ansielix is often prescribed to be taken with a meal to help improve tolerability. These side effects often lessen over time as the body adjusts to the medication.

Q: Does Ansielix cause weight loss?

Weight change is not a primary or guaranteed effect of Ansielix, but some research suggests certain patients may experience a modest amount of weight loss, particularly those with Type 2 Diabetes who are overweight or obese. The exact reason is not fully understood, but it may be due to a slight reduction in appetite and changes in how the body uses fat. Ansielix is not approved or indicated for weight loss, as its primary purpose is to lower blood sugar. Patients should discuss all treatment goals and concerns, including weight, with their healthcare provider.

How should Ansielix be stored and disposed of?

Storage Requirements

Ansielix (Alprazolam) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container must be tightly closed, and the product must be protected from both excess heat and moisture.

Due to its classification as a controlled substance, Ansielix must be stored out of the sight and reach of children to prevent accidental ingestion and misuse.

Disposal Instructions

Unused or expired Ansielix should be disposed of using authorized drug take-back programs, which is the preferred method for controlled substances. If a take-back option is unavailable, the Immediate-Release tablet is on the official list of medicines recommended for disposal by flushing down the toilet to minimize the risk of accidental exposure to others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

Equivalent of Ansielix found in:

A-Z Index: